A Bayesian Re-Analysis of the GALFLU Trial of high dose versus standard dose influenza vaccine against hospitalisation outcomes ✅ Just Accepted 🔗 https://bit.ly/45bt2DV
Clinical Infectious Diseases
@cidjournal.bsky.social
The world's leading journal on infectious diseases. Clinical ID, public health, microbiology, and everything in-between. Official publication of @idsainfo.bsky.social
Molecular Epidemiology and Drug Resistance of Extraintestinal Pathogenic Escherichia coli Bloodstream Isolates From Adults Worldwide (2011–2023) ✅ Just Accepted 🔗 https://bit.ly/4wGMVyE
Reconsidering Ambiguous Language in Infectious Disease Consult Recommendations 🔁 Repost 🔗 https://t.co/jyoRZRp1Xd
Clinical Infectious Diseases is now on Roon! Follow CID on this physician-only platform to discuss the latest infectious diseases research, exchange ideas and connect with colleagues across the medical community. Join the conversation: https://www.roon.com/doctors/p/cid
Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation 🔁 Repost 🔗 https://t.co/39qkmTHuBL
Skipping to conclusions: Is one negative follow-up blood culture sufficient in Staphylococcus aureus bacteremia? 🔁 Repost 🔗 https://t.co/H0L03k55Tp
The Clean Margin in Diabetic Foot Osteomyelitis: Conceptual Appeal, Practical Uncertainty ✅ Just Accepted 🔗 https://bit.ly/3TymMUa
Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial ✅ Just Accepted ⭐ Editor's Choice https://bit.ly/4yP0dKW
Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial
AbstractBackground. Innovative HIV-1 therapies, especially those with infrequent dosing, are a promising approach to advance progress toward the UNAIDS goa
bit.ly
Valve strands: to be or not to be… infective endocarditis? ✅ Just Accepted #IDTwitter 🔗 https://bit.ly/4pOE4sg
Persistence of Serum Bactericidal Antibody in the First 2-Years After Immunization with Pentavalent Meningococcal ACWYX Vaccine in Malian Infants and Toddlers ✅ Just Accepted 🔗 https://bit.ly/4x9BfEz
Detection-Dependent Classification of Valve Strands: How Much Does Imaging Intensity Drive the “Non-IE” Diagnosis? ✅ Just Accepted 🔗 https://bit.ly/4x8Z9jo
Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails ✅ Just Accepted 🔗 https://bit.ly/3Tu0fYD
Absence of Significant Interaction Between Serum Albumin Level and Carbapenem Type on 30-Day Mortality in ESBL-positive E. coli and K. pneumoniae Bacteremia: A Multicenter Study with Inverse Probability of Treatment Weighting Analysis ✅ Just Accepted 🔗 https://bit.ly/4x8HTuK
Impact of HIV-1 RNA Assay Selection on Low-Level Viremia and Clinical Trial Endpoint Interpretations ✅ Just Accepted ⭐ Editor's Choice 🔗 https://bit.ly/4pInWIC
Time to Antibiotics and Mortality in Immunocompromised versus Non-Immunocompromised Patients with Suspected Sepsis ✅ Just Accepted 🔗 https://bit.ly/4vO28g9
Routine serial follow-up blood cultures after a negative result within 48 hours of methicillin-susceptible Staphylococcus aureus bacteremia: low yield, high cost ✅ Just Accepted 🔗 https://bit.ly/4vVQvE1
Skipping to conclusions: Is one negative follow-up blood culture sufficient in Staphylococcus aureus bacteremia? ✅ Just Accepted ✍️ steventong.bsky.social 🔗 https://bit.ly/4gT9xXR
Bacteriophage therapy of Mycobacterium abscessus mastoiditis ✅ Just Accepted #IDTwitter 🔗 https://bit.ly/4c1VgVg
Incorporating ambient air pollution as a risk factor for tuberculosis mortality in Delhi, India ✅ Just Accepted 🔗 https://bit.ly/4fSAF8i
Optimizing HCV Screening to Maximize Health Benefit Among Men Who Have Sex with Men in the United States: A Cost-Effectiveness Analysis ✅ Just Accepted https://bit.ly/4x3gbzC
Optimizing HCV Screening to Maximize Health Benefit Among Men Who Have Sex with Men in the United States: A Cost-Effectiveness Analysis
There are no accepted measures to prevent sexually transmitted HCV among MSM. We therefore determined the optimal HCV testing strategy for treatment to res
bit.ly
A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam ✅ Just Accepted 🔗 https://bit.ly/4pCI4fm
Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024–25 season ✅ Just Accepted 🔗 https://bit.ly/3TxNyvO
The New Vaccine Surveillance Network: 25 years of active, population-based surveillance for pediatric infectious diseases in the United States ✅ Just Accepted 🔗 https://bit.ly/4feWu1H
Birth in the neonatal HBV vaccination era and hepatitis B surface antigen seroclearance in people with HIV and HBV coinfection on tenofovir-containing antiretroviral therapy ✅ Just Accepted https://bit.ly/3RoVbnM
Birth in the neonatal HBV vaccination era and hepatitis B surface antigen seroclearance in people with HIV and HBV coinfection on tenofovir-containing antiretroviral therapy
bit.ly
Correlates of Dolutegravir Resistance in Low- and Middle-Income Countries: A Combined Analysis of Drug Resistance Surveys in Four Countries ✅ Just Accepted 🔗 https://bit.ly/4fuuia0
Clostridioides difficile Infection Deceleration: What Is Next? ✅ Just Accepted 🔗 https://bit.ly/4bwh7UI
Correction to: Interest in Infectious Diseases Among Internal Medicine Resident Physicians: Results From a Nationwide Survey ✅ Just Accepted 🔗 https://bit.ly/4hnM1SW
